IPF Patients Taking High-dose Steriods for Acute Exacerbations May Have Poor Outcomes

IPF Patients Taking High-dose Steriods for Acute Exacerbations May Have Poor Outcomes

Idiopathic pulmonary fibrosis patients experiencing acute exacerbations (IPF-AE) who have a history of immunosuppression and high-dose steroid use are likely to have measurably worse survival outcomes than IPF-AE patients not under such treatment, a new study reported. The research article, “Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach,” was published…

#TBT – Remembering James Doohan

James Doohan was a Canadian actor best known for his role as Montgomery “Scotty” Scott in the television and film series Star Trek. Doohan died on July 20, 2005, at his home in Redmond, Washington due to complications of pulmonary fibrosis, which was believed to be from…

IPF Patients Able to Undergo Long-term Pirfenidone Treatment

Researchers from a large number of international institutions have published an integrated analysis showing that long-term treatment with pirfenidone (Esbriet, Genentech, Roche) in patients with idiopathic pulmonary fibrosis (IPF) can be considered safe. The study, “Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of…

Phase II Trial for Gilead’s IPF Therapy Simtuzumab Terminated After DMC Recommendation

Gilead Sciences, Inc. recently announced in a press release that it is stopping its RAINIER Phase II clinical trial testing the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF), noting that the experimental therapy did not demonstrate efficacy in treating the disease. Simtuzumab is a humanized monoclonal…

Pulmonary Fibrosis: Breathing with Help

https://www.youtube.com/watch?v=a9D2HUyud-k   Learn more about Pulmonary Fibrosis: http://bit.ly/1lfMsiZ Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of…

Pulmonary Fibrosis Among Top Projects in Expanding Research Partnership

MedImmune, AstraZeneca’s biologic research and development arm, announced that it is expanding its collaboration with the University of California, San Francisco (UCSF), to focus on basic research and translational sciences into diseases involving the Respiratory, Inflammation and Autoimmunity (RIA) fields. The partnership continues joint work begun in 2014, and the two will initiate about a half-dozen research projects…

IPF: Pirfenidone & Nintedanib as Treatment

“Dr. Timothy Whelan, Medical Director of the Lung Transplant Program from the Medical University of South Carolina, provides advice for two new drugs, Pirfenidone and Nintedanib, to slow the progression of IPF.” Read more about IPF and approved therapies: http://bit.ly/1lfMsiZ…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums